Tag: Ledipasvir

Over 90% of chronic hepatitis C (HCV) cases can now be cured with well-tolerated, oral direct-acting antiviral (DAA) medications. The landmark drug Harvoni (ledipasvir/sofosbuvir) revolutionized this treatment landscape upon its 2014 approval, offering a highly effective, interferon-free regimen for specific genotypes. Although newer pan-genotypic therapies have emerged, Harvoni is still used for certain patient profiles and indications.

Harvoni, a combination of the direct-acting antivirals ledipasvir and sofosbuvir, can be given for a duration of 8 to 24 weeks, depending on the patient's specific health profile. This advanced medication revolutionized hepatitis C treatment by offering high cure rates with a once-daily, single-tablet regimen.

Initially approved by the FDA in 2014, Harvoni was a landmark hepatitis C treatment offering cure rates of over 90% for specific genotypes. While newer, more versatile direct-acting antivirals (DAAs) have since emerged, the question remains: **is Harvoni still used** in current medical practice? The answer is yes, though its place in therapy has evolved.

Over 90% of people with chronic hepatitis C virus (HCV) can be cured with direct-acting antiviral (DAA) medications. Among these, Harvoni Tablet is used to treat specific genotypes of HCV infection in adults and certain children.